Background. About 10% of new diagnoses of subtype B human immunodeficiency virus type 1 (HIV-1) in the United Kingdom are with viruses showing transmitted drug resistance (TDR). However, there is discordance between the mutation patterns observed in HIV-infected patients failing therapy and those seen in TDR.
The use of highly active antiretroviral therapy (HAART) has dramatically reduced mortality and morbidity associated with infection with human immunodeficiency virus type 1 (HIV-1). However, virological failure when using HAART can lead to the emergence of drugresistant forms of HIV-1. As more individuals were treated, leading to higher levels of drug resistance in the population, the chance of new infections from resistant virus increased and transmitted drug resistance (TDR) was recognized. It has been standard practice in many localities to test newly infected individuals for the presence of resistant virus [1, 2] . In the United Kingdom, TDR, as defined by mutations designated by the World Health Organization [3] , peaked in 2002 at 15.5% in subtype B infections and then fell to 10.9% by 2009 [4] . The most pronounced decline has been in mutations associated with nucleotide reverse transcriptase inhibitors (NRTIs). The presence of TDR was shown to be associated with a higher risk of failure of first-line therapies, presumed to occur because these therapies are rendered suboptimal by the presence of drug-resistance mutations [5] . However, it has since been found that many mutations found in TDR are thought not to compromise current first-line therapies, with the exception of nonnucleoside reverse transcriptase inhibitors (NNRTIs) [4] due to the move away from zidovudine (AZT)-and stavudine-based therapies.
The stability of TDR mutations in untreated patients has been examined [6, 7] . It has been shown that while mutations such as K65R and M184V in reverse transcriptase are lost rapidly due to fitness costs, other mutations can persist for many years. T215Y/F mutations in reverse transcriptase, commonly observed in patients who fail therapies that include AZT or d4T, are quickly replaced with "revertant" mutations (T215rev) such as T215D/C/E/S following transmission [8] . These T215rev mutations have been found to persist for a median of 13.0 years (95% confidence interval, 6.6-25.7 years) [7] , thus providing considerable potential for onward transmission.
In recent years, most (60%-70%) resistance tests from treated patients show no resistance mutations, and there is a marked discordance between those mutations seen in failing patients and those seen in TDR [9, 10] . With the longevity of some TDR mutations, a substantial proportion of TDR may therefore be derived from untreated and possibly undiagnosed patients. Onward transmission of TDR was first reported in 2003 [11] , and an analysis of the UK HIV Drug Resistance Database (UKHDRD) in 2009 found 5 treatment-independent clusters of TDR [12] . In the Swiss HIV cohort study, it has recently been shown that treatment-naive individuals are the major source of TDR in men who have sex with men (MSM) [13] .
This report focuses on the source of the most common TDR mutations seen associated with resistance to NRTIs, NNRTIs, and protease inhibitors (PIs), namely, at codons T215, K103, and L90, which occurred in 4.0%, 2.8%, and 0.9%, respectively, of all new subtype B diagnoses in the United Kingdom between 2002 and 2009 [4] . We analyze the degree of linkage of sequences with these most common TDR mutations within drug-naive patients only and find evidence for considerable onward transmission.
METHODS

Resistance Tests
The UKHDRD includes the collation of the vast majority of genotypic-resistance tests conducted in the United Kingdom since the assay was first introduced as part of routine clinical care [14] . Partial pol sequences (encoding the protease gene and at least codons 34-234 of reverse transcriptase) generated by Sanger sequencing are transferred electronically from participating laboratories, which use a variety of commercial and in-house assays. A quality assurance program in which all noncommercial laboratories participate is carried out annually.
Tests in the present analysis were conducted between 1997 and 2011. Subtype was assigned using the REGA HIV-1 subtyping algorithm (version 2.0) [15, 16] .
Patients
All treatment-naive subtype B sequences with any of L90M, K103N, or T215 mutations (Y/F/revertants) were analyzed. The first available sequence was used for patients with 2 or more pretherapy tests. Duplicate samples were matched using clinical identifiers; if identifiers were missing, they were matched by identical dates of birth and very low genetic distance.
Phylogenetic Analysis
A FastTree maximum-likelihood tree was created using the general time reversible (GTR) model of nucleotide substitution with gamma-distributed rate variation among sites, following removal of resistance positions [17] . Clusters were selected with a bootstrap support ≥0.8 and a maximum genetic distance of ≤1.5% or ≤2.0% using the Jukes-Cantor distance method with partial inclusion of mixed bases. Thus, ambiguous sites were only included if they resulted in a definite nucleotide change, for example, A vs R (not included), whereas A vs Y (included). The 1.5% genetic distance represented <0.01 percentile of distribution of all pairwise distances for the sequences. Nine clusters had bootstrap support <0.8. Three of these had bootstrap support >0.77 and therefore were included. The remaining 6 clusters were analyzed at higher nodes to determine if an increase in maximum genetic distance threshold resulted in larger clusters with a high bootstrap support. The larger clusters were accepted if the nearest linkage to the additional sequences had a maximum genetic distance ≤2% or a maximum nearestneighbor distance below the threshold of 1.5%. The maximum nearest-neighbor distance is the largest value of all nearestneighbor distances in the cluster. Four clusters had ≥0.8 bootstrap support at a higher node with a maximum genetic distance <2%, whereas 2 clusters had ≥0.8 bootstrap support at a higher node and a maximum genetic distance >2% but a maximum nearest-neighbor distance <1.5%.
Estimating the Time of Origin and Basic Reproductive Number of TDR Clusters
The time of most recent common ancestor (tMRCA) of the large transmission clusters with 8 or more sequences identified using a maximum genetic distance threshold of ≤1.5% was estimated using a Bayesian Markov chain Monte Carlo (MCMC) approach as implemented in BEAST (Bayesian evolutionary analysis by sampling trees) software [18] . This corresponds to the date at which resistance mutations first occurred in the clusters. For computational reasons, the 624 sequences that formed highly supported clusters by the maximum-likelihood method were randomly divided into 4 smaller groups of approximately 150 sequences, keeping sequences in clusters together. This was repeated 2 times with different cluster combinations to test the robustness of the clusters and tMRCA estimates. The analysis was preceded by a comparison of different molecular clock (strict or relaxed), demographic (Bayesian Skyline Plot), and nucleotide substitution (GTR + gamma or SRD06) models using Bayes factor (with a Bayes Factor >20 level of significance). The convergence of the MCMC runs was evaluated using the generation vs log probability plots of important parameters with effective sample size >200 considered significant. The basic reproductive number (R 0 ), used here to signify the average number of secondary infections that will arise during the lifespan of an infection, was estimated using the birth-death model (BDM) as implemented in BEAST. This has been shown to provide a more accurate estimate of R 0 because it calculates the transmission and death rates independently [19] . Death in this model equates to sampling date, thus, the estimated R 0 in this instance mostly represents that of early or primary infections rather than of the patient's lifetime as these samples are from newly diagnosed treatment-naive patients. However, it is possible that some of the patients were diagnosed late and in chronic phase. All estimates were done by sampling every 5000th generation from 3 independent MCMC runs of 50 000 000 generations that were subsequently combined using LogCombiner v1.7.5 software with 10% burn-in.
RESULTS
Identification of TDR Clusters in Treatment-Naive HIV-1 Subtype B-Infected Patients
Overall, sequences from 1140 treatment-naive patients with L90M, K103N, and T215Y/F/rev mutations were analyzed, representing about half of sequences showing any TDR in the database. Of the patients, 78% (n = 889) were male and 70% (n = 798) were identified as MSM. The remaining patients had the following identified as risk factors: 7% (n = 77) heterosexual, 1% (n = 12) intravenous drug use, <1% (n = 4) use of blood products, and 22% (n = 249) unknown. The sample years were 1997-2011, with the majority (923) of sequences from 2004 to 2010, owing to improved coverage in the later time period.
Overall, 650 (57.9%) of the sequences showed T215 mutations, 423 (37.7%) had K103N, and 152 (13.3%) had L90M. A small number of sequences had 2 (6.8%) or all 3 (1.1%) of the mutations under study.
Fifty-five percent (624/1140) of sequences with these TDR mutations were found to cluster using a genetic distance cutoff of 1.5%. Figure 1A shows the numbers of TDR sequences with L90M, K103N, or T215rev mutations that fell into clusters and the distribution of cluster size. One hundred and ninety-three clusters were seen ranging in size from 2 to 15 sequences, with 115 (61%) of the clusters containing more than 2 sequences. Using a 2% cutoff ( Figure 1B) , 735/1140 (64.5%) fell into 183 clusters containing 2-19 sequences, with 107 (58.5%) clusters containing more than 2 sequences. The decrease in the number of clusters at 2% genetic distance cutoff is due to an increase in the size of clusters, some of which are a result of a merger of clusters from the 1.5% cutoff analysis. Table 1 shows the distribution of mutations in the clusters using a 1.5% cutoff, with all 3 single mutations showing at least 1 cluster with 10 or more sequences. Six clusters (with 2-6 sequences) were found to include sequences with some minor different mutation patterns such as addition or loss of 1 of the TDR mutations under study relative to the rest of the cluster ( Table 2) .
The effect of including 1000 randomly selected subtype B treatment-naive sequences from the United Kingdom with no TDR on the clustering of TDR sequences was also examined using the 1.5% genetic distance cutoff. This decreased the proportion of sequences forming clusters to 41%. Eighty-four percent of the original TDR clusters were unaffected, whereas 33 clusters (16%) were altered. Of these 33 clusters, 27 changed Figure 1 . Effect of varying genetic distance threshold cutoff on number and size of clusters. Clusters were selected with maximum genetic distance cutoffs of ≤1.5% (A) and ≤2% (B ) using the TN93 distance method. Each bar graph shows the number of sequences with L90M, K103N, or T215rev mutations that fell into clusters and the distribution of cluster size.
size, of which 16 showed the loss or addition of 1 sequence only, while 6 clusters were lost. In contrast, only 32% of sequences formed clusters using the 1000 randomly selected treatmentnaive sequences only.
Time of Origin and Basic Reproductive Number of TDR Clusters
The Bayesian inferred phylogenies retained all the large clusters identified by the maximum-likelihood method with high ancestral node supports ( posterior probability ≥0.75) except for 1 large cluster of 11 sequences containing the PI resistance mutation L90M, which was not maintained as a single cluster using the Bayesian method (Figure 2A ). We estimated that the time of origin of the oldest cluster was 2000 (1999-2002; 95% highest posterior density [HPD] ) and that this lineage had persisted for approximately 8 years. The cluster was formed of 9 sequences, each containing the T215rev resistance mutations. The youngest cluster was found to have originated in 2006 (2005-2007; 95% HPD) and was also formed of 9 sequences, each containing T215rev resistance mutations. This cluster had persisted for nearly 4 years. Overall, the internal structure of most of the clusters shows that transmission events were distributed evenly over time, suggesting sustained subepidemics of the TDR mutations (Figure 2A and 2B) . To investigate this further, we determined the R 0 of each cluster that represents the number of infections each case generates on average over the course of the primary infection or until diagnosis, with an R 0 >1 suggesting a sustained spread of the lineage and vice versa. The analysis revealed that all 10 large clusters had R 0 s >1 ( Figure 2C ). The lowest estimate of R 0 was 1.3 (0.4-2.5; 95% HPD) for the second youngest cluster of 8 sequences containing the T215rev resistance mutations. The highest R 0 was 2.8 (0.6-6.5; 95% HPD) and again was for a cluster of 8 sequences containing T215rev resistance mutations. In addition, we determined whether within-cluster diversity had a relationship with the estimated R 0 . We plotted the maximum genetic distance of 13 TDR-containing transmission clusters against their estimated R 0 s (Figure 3 ). This showed no significant correlation, Pearson correlation of 0.32 (P = .29), as did size or age of each cluster, Pearson correlation of 0.29 (P = .41) and −0.25 (P = .49), respectively.
DISCUSSION
Here, we describe the degree of relatedness of sequences from treatment-naive subtype B-infected patients who carry the most common TDR mutations for each of the major drug classes. We demonstrate that a considerable proportion of TDR in the United Kingdom is linked to other TDR from untreated patients, although it could be concluded from this study that some treated patients transmitted to several uninfected people. However, for a mutation such as L90M, which is associated with drugs no longer used for treatment in the United Kingdom, it is unlikely that the sustained transmission of viruses containing this mutation is from treated patients. In addition, a similar observation was reported recently using the smaller database of the Swiss cohort [13] . This is not an unexpected result since the most common mutations seen in TDR, even in recent diagnoses, are not representative of those mutations seen in treatment failure in current patients [9] . Using the cluster definition provided above, it was found that 55%-65% of the sequences analyzed clustered with at least 1 other sequence, depending on the genetic distance threshold used to define a cluster, with the majority of clusters including more than 2 sequences. All 3 mutations examined were represented in clusters containing 10 sequences. This level of clustering is Figure 2 . Estimation of the time of origin and basic reproductive number (R 0 ) of large transmission clusters (≥8 sequences) using a Bayesian Markov chain Monte Carlo approach. A, Phylogenies of large clusters showing the time of origin. The mutation(s) and the number of sequences (in brackets) contained in each cluster are indicated next to each cluster. The Bayesian posterior probability for the node subtending each cluster is shown next to the node. B, Graphical representation of the time of origin of the clusters (black dot) with 95% highest probability density (HPD) interval (black line) and time of sampling of the data in the clusters (black circles). The time of origin of the clusters was estimated to range from 2000 to 2006. C, Estimation of the R 0 , that is, the number of cases 1 case generates over the course of its infectious period using a Bayesian method of phylogenetic analysis based on the birth-death model. An R 0 >1 indicates an ability of the infection to spread. The graph shows the R 0 for each cluster ranging from 1.3 to 2.8 (black dot) with 95% HPD intervals (black line). The gray bars indicate the number of sequences in each cluster. The clusters are numbered 1 to 10 in all panels. Cluster 8 (containing 11 sequences with L90M mutation) is the only large cluster that was not maintained when sequences were randomly divided into smaller groups of approximately 150 sequences for Bayesian phylogenetic inference and therefore is not represented in panel A. slightly higher than that observed using all subtype B sequences in the UKHDRD, which is approximately 30%-1.5% genetic distance and 90% bootstrap support (A. Leigh-Brown, personal communication). We also observed a similar level of clustering using 1000 randomly selected subtype B treatment-naive sequences from the database. This suggests that sequences from treatment-naive patients carrying the most common TDR mutations show a slightly greater degree of epidemiological linkage than seen overall in the database.
From the data analyzed here, it is not possible to know whether all the TDR has been transmitted while the source was still untreated. However, since 82% of new infections are estimated to be derived from the undiagnosed (and therefore untreated) [20] and the proportion of patients failing treatment with resistance is small, it seems likely that the continuing major source of TDR in the United Kingdom is from untreated patients. However, it was not possible to confirm that TDR was more likely to cluster in recent diagnoses compared with older ones due to the incomplete sampling prior to guidance to apply resistance tests to all new diagnoses.
Surveillance of TDR levels in the United Kingdom was first undertaken due to concern that the improvement in outcomes of HIV-infected patients following the introduction of HAART might be undermined if substantial levels of TDR occurred. Such concerns remain due to the reported level of TDR remaining stubbornly at about 10% of new MSM diagnoses. However, the data presented here indicate that a substantial proportion of TDR is derived by onward transmission from untreated patients, and it has previously been commented that TDR of 215 revertants in RT and L90M in protease are unlikely to compromise current first-line treatments in use in the United Kingdom [4] . Nevertheless, resistance testing on diagnosis remains clinically important in order to exclude the presence of the major NNRTI mutations such as K103N.
While the continuing transmission of TDR occurs, it may be that it will not be possible for the prevalence of TDR to fall to insignificant levels, despite the observation that a substantial minority of the TDR sequences did not cluster together. It is possible that this indicates no further transmission, though this may also be due to missing data. Although R 0 was estimated to be >1 for the large clusters examined, it is worth noting that the lower bounds of the credible intervals for all estimated R 0 s were <1, indicating a possibility that these particular TDR subepidemics could die off in due course. This may account for the observed decline in NRTI TDR, where the majority of mutations such as T215rev and its associated less prevalent mutations such as M41L and K219Q/N/E/R are seldom being generated de novo in treated patients due to decline in use of AZT and d4T. Likewise, L90M continues to be seen in approximately 1% of new diagnoses despite seldom being selected by current therapies, with many of the sequences that carry this mutation falling into large clusters with tMRCAs going back to early 2000s. This is in keeping with the period when drugs associated with these mutations, such as Saquinavir, Nelfinavir, d4T, and AZT, were first approved for use in Europe (mid-to late 1990s). Similar long transmission chains have been reported in the Swiss cohort [12] , confirming the slow rates of reversion of some TDR mutations [7] . In contrast, K103N is still associated with failure of current first-line regimens, so the potential for transmission from treated patients remains. Enhanced testing to reduce late diagnosis would potentially reduce the risk of onward transmission of TDR by initiating early treatment with appropriate regimens.
Use of the BDM to estimate the R 0 from serially sampled sequences is an advance on previous methods that use the coalescent [19, [21] [22] [23] . This is because the model can estimate the birth and death rates separately; these rates are required to infer the period of infectiousness. A limitation of the BDM method is that it assumes the subepidemic is in the exponential phase of growth. However, the tree topology of the transmission clusters seems to suggest that this is probably not true for all the clusters in this study, as some contain late long branches that indicate that they could be in a post-exponential or plateau phase. This could imply a decrease in the pool of susceptibles that would probably result in an underestimation of the R 0 [24] . Therefore, our estimates for the R 0 could be conservative. In addition, we show that within-cluster diversity has little effect on the estimated R 0 , as did size and age of the clusters, confirming previous findings [19] .
It is reassuring to note that much of the TDR in the United Kingdom is likely to be derived from untreated and likely undiagnosed individuals and that it is highly unlikely to have Figure 3 . Relationship between estimated basic reproductive number (R 0 ) and within-cluster diversity. The maximum genetic distance of 13 transmitted drug resistance clusters from treatment-naive individuals were plotted against their estimated R 0 s. The maximum genetic distance ranged from 0.9% to 4.4%, the R 0 s from 1.3 to 3.3, and cluster sizes from 8 to 28 sequences. Abbreviation: R 0 , basic reproductive number.
considerable impact on therapy outcomes. However, the same cannot be presumed for developing countries where therapy options and laboratory monitoring are much more limited.
Notes
